©2022 Stanford Medicine
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
Recruiting
I'm InterestedTrial ID: NCT02215928,
Purpose
This research trial studies using genomic profiling to recommend anticancer treatment to
patients with cancer that has spread beyond the original site of the tumor (metastatic
cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect
genetic changes or abnormalities. This information can then be used to recommend treatments
that may be more likely to result in a beneficial response. It is not yet known whether
genomic profiling will detect abnormalities that can be used to make treatment
recommendations and whether treatment based on genomic profiling is more effective than
standard treatment.
Official Title
Tumor Genomic Profiling: A Personalized Medicine Approach
Stanford Investigator(s)
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Eligibility
Inclusion Criteria:
- Understand and provide written informed consent and Health Insurance Portability and
Accountability Act (HIPAA) authorization prior to initiation of any study-specific
procedures
- Have a diagnosis of metastatic, incurable cancer and have progressed on at least one
line of systemic therapy OR a cancer with no standard 1st-line systemic therapy shown
to prolong survival (or where a clinical trial recommended as the 1st-line option)
- Measurable disease (RECIST 1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- In the opinion of the investigator, be medically suitable for and willing to undergo a
biopsy or surgical procedure to obtain tissue as a part of routine care for their
malignancy OR have adequate archival tissue from a previous biopsy available for
profiling
- Female patients of childbearing potential must have a negative pregnancy test and
agree to use at least one form of contraception during the study and for at least one
month after treatment discontinuation; for the purposes of this study, child-bearing
potential is defined as: all female patients that were not in post-menopause for at
least one year or are surgically sterile
- Male patients must use a form of barrier contraception approved by the
investigator/treating physician during the study and for at least one month after
treatment discontinuation
Exclusion Criteria:
- Have lesions that are not accessible to biopsy or not planned for biopsy as part of
routine care OR if archival tissue will be used for profiling, an insufficient amount
is available
- Have diagnosis of a hematologic malignancy
- Have symptomatic central nervous system (CNS) metastasis; patients with a history of
CNS metastases who have been treated with whole brain irradiation must be stable
without symptoms for 4 weeks after completion of treatment, with image documentation
required, and must be either off steroids or on a stable dose of steroids for >= 2
weeks prior to enrollment
- Have uncontrolled concurrent illness including, but not limited to, ongoing or active
serious infection, symptomatic congestive heart failure, unstable angina pectoris,
unstable cardiac arrhythmias, psychiatric illness, or situations that would limit
compliance with the study requirements or the ability to willingly give written
informed consent
- Have known human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C
virus (HCV) infection
- Are pregnant or breast-feeding patients or any patient with childbearing potential not
using adequate contraception
Intervention(s):
genetic: mutation analysis
other: cytology specimen collection procedure
other: laboratory biomarker analysis
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Meredith Mills
650-724-5223